Leidos vs Science Applications Intl
Leidos reported revenue of $17.2 billion in fiscal 2025, 2.4 times Science Applications Intl's $7.3 billion in fiscal 2026. Leidos' revenue grew 3.1% in its latest year, and Science Applications Intl's fell 2.9%. Leidos had an operating margin of 12.3%, against 7.2% at Science Applications Intl. Free cash flow was $1.6 billion at Leidos and $577 million at Science Applications Intl. Their fiscal years end in different months (January 2 and January 30), so the periods don't line up exactly.
Side by side
| Leidos | Science Applications Intl | |
|---|---|---|
| Latest fiscal year | FY2025, Jan 2, 2026 | FY2026, Jan 30, 2026 |
| Revenue | $17.2B | $7.3B |
| Revenue growth | 3.1% | −2.9% |
| Revenue growth a year, last 5 years | 6.9% | 0.6% |
| Gross margin | 18.0% | 12.0% |
| Operating margin | 12.3% | 7.2% |
| Net margin | 8.4% | 4.9% |
| Free cash flow | $1.6B | $577M |
| Free cash flow margin | 9.5% | 8.0% |
| Return on capital | 19.2% | 12.8% |
| Net debt to EBITDA | 1.5x | 4.2x |
| Dividends and buybacks | $611M | $515M |
| Change in diluted share count | −4.4% | −7.9% |
| Last close | $139.86 | $148.51 |
| P/E at the last close | 13.1× | 17.3× |
| Insider trades, last 12 months | sold $3.2 million | bought $478,727, sold $0 |
| Piotroski F-score | 9 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
LeidosScience Applications Intl
Operating margin
Percent of revenue
LeidosScience Applications Intl
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
LeidosScience Applications Intl
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Leidos and Science Applications Intl pages.